Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Norketotifen - Emergo Therapeutics

Next Previous
Drug Profile

Norketotifen - Emergo Therapeutics

Alternative Names: NKT; Nor-ketotifen

Latest Information Update: 10 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emergo Therapeutics
  • Class Antiallergics; Antihistamines; Antivirals; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic rhinitis; Allergic rhinoconjunctivitis; Influenza virus infections

Most Recent Events

  • 05 Oct 2022 Norketotifen is still in phase II trials for Influenza virus infections in USA (Emergo Therapeutics pipeline, October 2022)
  • 09 Feb 2022 Emergo Therapeutics completes a phase IIb trial in Influenza virus infections in USA (NCT04610047)
  • 14 Dec 2020 Emergo Therapeutics initiates a phase IIb trial in Influenza virus infections in USA (NCT04610047)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top